Biomarkers Market size to US$ 278 Bn by 2032 at 15.3% CAGR Industry trends and forecasts by Fact.MR

The global sales of Biomarkers in 2021 was held at US$ 59.1 Bn. With 15.3%, the projected market growth during 2022 – 2032 is expected to be significantly higher than the historical growth.

Key Points Covered in Biomarkers Industry Survey:

  • Market Estimates and Forecasts (2017-2032)
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis
  • COVID-19 Impact on Biomarkers and How to Navigate
  • Recommendation on Key Winning Strategies

Request a report sample to gain compressive insights at@

Diagnostic biomarkers are used only in symptomatic patients, as opposed to screening biomarkers, which are only applicable to symptomatic individuals. Interestingly, the properties of ideal diagnostic biomarkers are similar to those of screening. In particular, the most established biomarkers for screening can be used as diagnostic markers. Currently available cancer biomarkers are still less diagnostically sensitive and specific with respect to the limitations encountered with diagnostic biomarkers. However, diagnostic biomarkers must be sensitive in order to be good diagnostic biomarkers.

Competitive Analysis

The key players such as F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Epigenetics AG; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc. adopt several organic and inorganic strategies to enhance their revenue and market standings.

Some of the recent developments of key Biomarkers providers are as follows:

  • In May, 2021, Cerascreen KRAS RGQ PCR Kit, the first FDA-approved diagnostic tissue specimen to identify KRAS G12C mutations in QIAGEN NV NSCLC tumors and expand precision medical options for lung cancer, was launched.
  • In April, 2021, F. Hoffmann La Roche Ltd. launched two cardiac biomarker tests, the Sensitive Cardiac Troponin T (cTnThs) and the N-Terminal Pro Brain Sodium Diuretic Peptide Test (NTproBNP). These gold standard biomarkers support the management of cardiovascular disease and may help physicians diagnose heart attacks and better manage heart failure.
  • In July 2020, Thermo Fisher Scientific has signed an agreement with Chugai to expand the use of oncomin Dx targeted tests in patients with non-small cell lung cancer (NSCLC) and accelerate local biomarker tests.
  • In January 2020, in partnership with the Institute for Microbial Technology (CSIRIMTECH), Merck KGaA opened a research institute in Chandigarh, India, with a focus on genome editing, biomarker detection, and life sciences. The facility is equipped with cutting-edge technology needed for on-site students.

To learn more about Biomarkers Market, you can get in touch with our Analyst at@

Market Segments Covered in Biomarkers Industry Analysis
·         By Disease Type :
    • Cardiovascular Diseases
    • Cancer
    • Neurological Diseases
    • Immunological Diseases
    • Other Disease Types
·         By Type :
    • Safety
    • Efficacy
    • Validation
·         By Application :
    • Diagnostics
    • Drug Discovery & Development
    • Personalized Medicines
    • Other Applications

To Remain ‘Ahead’ of Your Competitors, Buy the Report Now!

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office :

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583



Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Visit Our Website: